Cross Linking News and Research

RSS

MiMedx awarded QTDP grant for CollaFix drug delivery device

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has been awarded a Qualifying Therapeutic Discovery Project grant (QTDP) from the U.S. Government. The grant, in the amount of $244,479, has been made to defer some of the Company's research expenditures related to the development of its novel and patented technology, CollaFix™, as a drug delivery device.

2 Dec 2010

Avedro's KXL System for corneal cross-linking granted European CE Mark

Avedro, Inc., sponsor of two completed US FDA multi-center clinical trials for corneal cross-linking, today announced that its KXL™ System for performing accelerated corneal cross-linking (KXL) has received the European Union's CE Mark. The CE Mark certifies that the KXL System has met the EU's health and safety standards and opens the door to immediate commercialization across the European Economic Community and in other countries recognizing the CE Mark.

17 Nov 2010

InNexus receives $116,760 cash grant under QTDP program to develop DXL anti-cancer antibodies

InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.

8 Nov 2010

CR4354 antibody uses crosslinking mechanism to neutralize West Nile virus

Researchers have learned the structure that results when an antibody binds to the West Nile virus, neutralizing the virus by locking up its infection mechanism. The information could help scientists develop a vaccine against the mosquito-borne disease.

3 Nov 2010

Antigene therapy uses light energy to silence gene activity: Review article

Antigene therapy is a promising new treatment strategy that uses a DNA-based drug to pinpoint light energy to a target gene shutting down its activity.

22 Oct 2010

Covidien to showcase innovative surgical products at 96th ACS Clinical Congress

Covidien, a leading global provider of healthcare products, will preview new devices and showcase some of the Company's most innovative products at the 96th Annual Clinical Congress of the American College of Surgeons.

5 Oct 2010

Cornea and Laser Eye Institute to study CXL effectiveness in keratoconus patients

The Cornea and Laser Eye Institute, with Principal Investigator, Peter S. Hersh M.D., is conducting a research study to study the safety and effectiveness of corneal collagen crosslinking (CXL) using Riboflavin/Dextran and Hypotonic Riboflavin in patients with progressive keratoconus and corneal ectasia.

17 Sep 2010

Studies provide evidence for new approach to MRSA vaccines

Two recent studies provide evidence for a new approach to vaccines to prevent infections caused by drug-resistant Staphylococcus aureus -- better known as MRSA - the leading cause of skin and soft tissue, bloodstream and lung infections in the United States. One demonstrates a way to counteract the bacteria's knack for evading the immune system. The other shows how to disrupt the germ's tissue-damaging mechanism.

17 Aug 2010

Researchers discover enzyme crucial for DNA repair

Researchers have discovered an enzyme crucial to a type of DNA repair that also causes resistance to a class of cancer drugs most commonly used against ovarian cancer.Scientists from The University of Texas MD Anderson Cancer Center and the Life Sciences Institute of Zhejiang University in China report the discovery of the enzyme and its role in repairing DNA damage called cross-linking in the Science Express advance online publication of Science.

30 Jul 2010

InNexus Biotechnology, NCI amend Collaborative Agreement

InNexus Biotechnology Inc., a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced the Company and the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), have amended the Collaborative Agreement announced on May 27, 2010, involving research on technologies developed by InNexus.

2 Jul 2010

ESHRE's EIM: Europe leads in Assisted Reproduction Technology

Europe leads the world in Assisted Reproduction Technology (ART) with most cycles initiated in the region, the 26th Annual Meeting of the European Society of Human Reproduction and Embryology heard today (Wednesday 30 June).

30 Jun 2010

InNexus develops IXS312 small protein fragment as topical therapy for AMD, diabetic retinal dysplasia

InNexus Biotechnology Inc., a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced that it has developed IXS312(VEGF), an antibody fragment with activity against the growth factor VEGF for planned use in ocular treatments.

30 Jun 2010

InNexus Biotechnology announces research Collaboration Agreement with National Cancer Institute

InNexus Biotechnology Inc., a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced the Company has entered into a Collaboration Agreement with the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH) to research proprietary technologies developed by InNexus.

28 May 2010

WPI, Cerus announce positive results from study of INTERCEPT Blood System to inactivate XMRV

The Whittemore Peterson Institute for Neuro-Immune Disease (WPI) and Cerus Corporation announced positive results from a study demonstrating the efficacy of the INTERCEPT Blood System to inactivate XMRV, a human retrovirus, in donated platelet components.

18 May 2010

New light-activated Photochemical Tissue Bonding technology helps treat battlefield injuries

Airmen's traumatic battlefield injuries may be more effectively treated by using a new light-activated technology developed as a result of research managed by Air Force Office of Scientific Research and supported by funds from the Office of the Secretary of Defense.

4 May 2010

New production method yields hundredsfold more ubiquitylated proteins critical for cancer research

Scientists at the University of Delaware have developed a new method for producing proteins critical to research on cancer, Alzheimer's, and other diseases.

3 Apr 2010

Avedro to acquire Corneal Collagen Crosslinking Phase III study rights from Peschke Meditrade

Avedro, Inc. today announced it has signed a definitive agreement with Swiss-based Peschke Meditrade GmbH to acquire the rights to its Phase III studies of Corneal Collagen Crosslinking for the treatment of progressive keratoconus and post LASIK ectasia. The two randomized, controlled, multi-site clinical trials are designed to assess the safety and efficacy of riboflavin/ultraviolet-A light for halting the progression of these degenerative disorders and the accompanying decline in patient’s visual acuity.

17 Mar 2010

Study sheds light on how CL-HA stimulates collagen repair in skin

In the U.S. and around the world, the popularity of minimally invasive cosmetic procedures continues to increase. Soft tissue injectables, also known as dermal fillers, are popular procedures that improve the appearance of aging and sun-damaged skin by restoring lost volume and filling lines.

5 Mar 2010

Neomend completes $30M Series D funding round

Neomend, Inc., an innovator in sealant and adhesion-prevention products for the surgical marketplace, announced today it has completed a funding round of $30 million, with Clarus Ventures, LLC investing $17 million.

28 Jan 2010

Neomend receives premarket approval from FDA for ProGEL Pleural Air Leak Sealant

Neomend, Inc., an innovator in sealant and adhesion-prevention products for the surgical marketplace, announced it has received premarket approval from the U.S. Food and Drug Administration (FDA) for the company’s ProGEL™ Pleural Air Leak Sealant.

20 Jan 2010